LianBio

CompanyUnited States

LianBio develops 2 assets, the furthest approved, not sold in the US (infigratinib). Mostly small molecule acting on FGFR1, FGFR4 and fgfr3; based in the United States.

2
Assets
Furthest stage
Approved, not sold in the US
Raised
$638M
5
Trials
67
Signals

Pipeline

2
  • infigratinib

    Inhibits FGFR1, FGFR2 and FGFR3 signaling to suppress tumor growth.

    Approved, not sold in the US, Small molecule, FGFR1, FGFR4, achondroplasia (Phase 3), advanced cholangiocarcinoma (Phase 3)

  • mavacamten

    Inhibits cardiac myosin ATPase activity, reducing excessive actin–myosin cross-bridge formation and cardiac contractility.

    Approved, Small molecule, MYH7, MYL3, Symptomatic Obstructive Hypertrophic Cardiomyopathy, Cardiomyopathy, Hypertrophic

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms12
  • Trials5
  • Funding rounds and grants3
  • Deals2
  • Signals20
  • Similar companies6

Intelligence